CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $4.87B, above the global median of $1.15B
- FinancialsAltman Z-Score 1.94: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
32.51BCNY4.87B · vs all stocks (USD)
Revenue (TTM)
3.03BCNY453.54M · vs all stocks (USD)
Profit Margin
-14.57%vs Biotechnology peers
Beta
0.5190xvs all stocks
52-Week Change
-18.18%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
32.51BCNY4.87B · vs all stocks (USD)
Enterprise Value
33.42BCNY5.01B · vs all stocks (USD)
Forward P/E
433.29xvs Biotechnology peers
Price to Sales (TTM)
10.28xvs Biotechnology peers
Price to Book (MRQ)
5.23xvs Biotechnology peers
Enterprise to Revenue
11.04xvs Biotechnology peers
Enterprise to EBITDA
-97.02xvs Biotechnology peers
Gross Margin
74.66%vs Biotechnology peers
Profit Margin
-14.57%vs Biotechnology peers
Operating Margin
-5.25%vs Biotechnology peers
Return on Assets (TTM)
-2.89%vs Biotechnology peers
Return on Equity (TTM)
-9.32%vs Biotechnology peers
Revenue (TTM)
3.03BCNY453.54M · vs all stocks (USD)
Revenue per Share (TTM)
2.87CNYUpdated Oct 24, 2026Quarterly Revenue Growth
45.20%vs Biotechnology peers
Gross Profit (TTM)
2.33BCNY349.14M · vs all stocks (USD)
EBITDA (TTM)
-344.45MCNY-51.62M · vs all stocks (USD)
Net Income (TTM)
-440.82MCNY-66.07M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
58.83%vs Biotechnology peers
Operating Cash Flow (TTM)
-258.74MCNY-38.78M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-687.59MCNY-103.05M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00CNYUpdated Oct 24, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Minority Interest (Equity)
26.16MCNYFY2025 · Dec 31, 2025Revenue
2.50BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
522.76MCNYFY2025 · Dec 31, 2025Gross Profit
1.98BCNYFY2025 · Dec 31, 2025Operating Income
-925.10MCNY-138.64M · vs all stocks (USD)
Pre-tax Income
-986.57MCNYFY2025 · Dec 31, 2025Income Tax Expense
-13.88MCNYFY2025 · Dec 31, 2025Net Income
-972.69MCNYFY2025 · Dec 31, 2025EBIT
-911.80MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-774.30MCNYFY2025 · Dec 31, 2025Research & Development
1.38BCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.57BCNYFY2025 · Dec 31, 2025Non-operating Interest Income
31.89MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
74.77MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.8400CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.8400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.01BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.01BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-986.57MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
131.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-768.45MCNYFY2025 · Dec 31, 2025Free Cash Flow
-1.54BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.59BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-986.57MCNYFY2025 · Dec 31, 2025Stock-based Compensation
77.15MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-10.93MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
16.10MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
135.81MCNYFY2025 · Dec 31, 2025Capital Expenditures
-768.27MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-26.00KCNYFY2025 · Dec 31, 2025Net Acquisitions
-369.71MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.77BCNYFY2025 · Dec 31, 2025Sale of Investments
2.28BCNYFY2025 · Dec 31, 2025Other Investing Activity
5.31MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.62BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
3.58BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.40BCNYFY2025 · Dec 31, 2025Common Stock Repurchase
0.00CNYFY2025 · Dec 31, 2025Other Financing Charges
241.60MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
2.37BCNYFY2025 · Dec 31, 2025Shares Outstanding
1.03BSharesUpdated Oct 24, 2026Float Shares
753.17MSharesUpdated Oct 24, 2026% Held by Insiders
31.00%vs all stocks
% Held by Institutions
18.95%vs all stocks
Total Cash (MRQ)
3.82BCNY571.96M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.72CNYUpdated Oct 24, 2026Total Debt (MRQ)
5.91BCNY886.31M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9614xvs Biotechnology peers
Current Ratio (MRQ)
1.80xvs Biotechnology peers
Book Value per Share (MRQ)
5.79CNYUpdated Oct 24, 2026Total Assets
12.40BCNY1.86B · vs all stocks (USD)
Total Current Assets
4.46BCNYFY2025 · Dec 31, 2025Total Liabilities
6.33BCNYFY2025 · Dec 31, 2025Total Non-current Assets
7.94BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
3.51BCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.81BCNYFY2025 · Dec 31, 2025Cash
2.59BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.59BCNYFY2025 · Dec 31, 2025Other Short-term Investments
600.78MCNYFY2025 · Dec 31, 2025Accounts Receivable
506.44MCNYFY2025 · Dec 31, 2025Inventory
573.11MCNYFY2025 · Dec 31, 2025Accounts Payable
1.46BCNYFY2025 · Dec 31, 2025Short-term Debt
1.29BCNYFY2025 · Dec 31, 2025Long-term Debt
2.85BCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.03BCNYFY2025 · Dec 31, 2025Retained Earnings
-11.16BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
6.07BCNY910.20M · vs all stocks (USD)
Treasury Stock
30.89MCNYFY2025 · Dec 31, 202552-Week Low
28.10CNYUpdated Oct 24, 202652-Week High
46.55CNYUpdated Oct 24, 202652-Week Change
-18.18%vs all stocks
Beta
0.5190xvs all stocks
50-Day MA
34.24CNYUpdated Oct 24, 2026200-Day MA
35.44CNYUpdated Oct 24, 2026Avg 10-Day Volume
10.20MSharesUpdated Oct 24, 2026Avg 30-Day Volume
11.14MSharesUpdated Oct 24, 2026Diluted EPS (TTM)
-0.4000CNYUpdated Oct 24, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.75Profit Margin: -0.15
Financial Health
Altman Z-Score 1.94: grey zoneSignificant
Altman Z-Score: 1.94
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $4.87B, above the global median of $1.15BNotable
Market cap (USD): 4,872,265,765.882Global Median: 1,150,342,212.262
Companies that share the same coordination system — how they create, deliver, or capture value.
Veradermics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Iovance Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Erasca, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Tibet Cheezheng Tibetan Medicine Co. Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
DukSan Neolux Co.,Ltd
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Infortrend Technology Inc.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated